Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.
Cancer
DRUG: SOR-C13
Toxicity graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0, Over 21 days from initial administration
Plasma levels of SOR-C13, Pre-treatment and up to 4 hours post-treatment on Study Days 1, 3, 8 and 10
The purpose of this study is to determine the safety and tolerability of the drug SOR-C13 when given as an intravenous infusion in patients with ovarian cancer or other cancers known to over express the TRPV6 calcium channel.